PUBLIC COMPANY
save$BEAMBeam Therapeutics Inc.
$BEAM24.50+0.45%Cambridge, MA, USupdated 1d ago
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.
community read0 votes
pipeline
5
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(5)
pipeline depth5 products
1Preclinical4Phase 2
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
- —A Long-term Follow-up Study in Patients Who Received BEAM-101
- phase1This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects
- phase2BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
- phase2A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
- phase2A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
🐶 Hiring Signal
next earnings Nov 3, 2026
Where Beam Therapeutics Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaHematology 4Metabolic 1
News
- STAT+: Up and down the ladder: The latest comings and goingsFrom new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.stat · 2d ago
- STAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and moreThe U.S. approved 10 drugmakers to participate in a 340B pilot program that will allow them to offer rebates, instead of upfront discounts, to certain providersstat · 2d ago
- Mistrust in science and a juicy gene-editing lawsuitWhy have so many Americans lost trust in science? And what's the deal with a new gene-editing lawsuit? Find out on this week's episode of "The Readout LOUD" podcast.stat · 3d ago
- STAT+: Pharmalittle: We’re reading about a plan to lower Medicare drug prices, a Lilly obesity drug, and moreA final Medicare rule aimed at lowering prices for doctor-administered drugs applies to only four companies and saves 96% less than the initial proposalstat · 3d ago
- STAT+: In Shanghai’s ‘Science City,’ China’s ascendant biotechs make their pitch to the worldA small conference with big ambitions mirrors the rapid growth of Chinese biotech, invites comparisons to U.S. biotech gathering also known for deal-making.stat · 4d ago
- STAT+: HHS announces new efforts to speed up, expand clinical trials with AIFederal health officials want to speed up clinical research to compete with countries like China.stat · 4d ago
- STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trialAn investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.stat · 4d ago
- STAT+: Three biotech updates, including accusations of theft and and a new lobbying leaderBeam Therapeutics has filed a lawsuit alleging one of its former scientists stole intellectual property and used it to co-found a Chinese company that recently made a deal with prominent VC…stat · 4d ago
- STAT+: Pharmalittle: We’re reading about Beam suing over IP theft, a Trump rule on importing meds, and moreGene-editing company Beam Therapeutics is alleging that one of its scientists stole intellectual property and used it to co-found a Chinese companystat · 4d ago
- Beam Therapeutics sues base editing rival, claims former scientist stole secretsBase editing biotech Beam Therapeutics is suing one of its newest rivals, alleging that the upstart company stole the secrets behind one of its lead programs and used them to craft a competing ther…fiercebiotech · 5d ago
Data sources
last refreshed 24m ago
Found something off?
comments(0)
5-min edit window · permanent after that